Innate Pharma Files 6-K, Submits Form 20-F
Ticker: IPHYF · Form: 6-K · Filed: Apr 15, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 6-K, 20-F
TL;DR
Innate Pharma filed its 6-K, confirming 20-F submission. Standard compliance.
AI Summary
Innate Pharma SA filed a Form 6-K on April 15, 2024, reporting as a foreign private issuer. The filing indicates the company is submitting its annual report under Form 20-F. The company's principal executive office is located at 117 Avenue de Luminy, Marseille, France.
Why It Matters
This filing is a routine regulatory submission for foreign private issuers, indicating Innate Pharma is complying with its reporting obligations to the SEC.
Risk Assessment
Risk Level: low — This is a routine regulatory filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (company) — SEC File Number
- 117 Avenue de Luminy (company) — Principal Executive Office Address
- Marseille, France (company) — Location of Principal Executive Office
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to submit information that the company makes or is required to make public in its home country.
Which annual report form is Innate Pharma submitting?
Innate Pharma is submitting its annual report under cover of Form 20-F.
What is the filing date of this report?
The report was filed on April 15, 2024.
Where is Innate Pharma's principal executive office located?
Innate Pharma's principal executive office is located at 117 Avenue de Luminy, Marseille, France.
What is the SEC file number for Innate Pharma?
Innate Pharma's SEC file number is 001-39084.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-04-15 06:00:39
Filing Documents
- a2404126kiph.htm (6-K) — 9KB
- exhibit991-2404121.htm (EX-99.1) — 15KB
- 0001598599-24-000026.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date April 15, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer